1

1 COVID-19 and acute kidney injury in German hospitals

2 **2020**

3 4	COVID-19 and AKI in Germany
5	
6	
7	
8	
9	Victor Walendy ¹ , Matthias Girndt ¹ , Daniel Greinert ¹
10	
11 12 13 14 15 16 17 18	1 Department of Internal Medicine II Medical Faculty of the Martin-Luther-University Halle-Wittenberg Ernst-Grube-Straße 40 D-06120 Halle (Saale) Germany
19	Corresponding author:
20	Victor.walendy@uk-halle.de

2

22 Abstract

23 Introduction

The SARS-CoV-2 pandemic is a major challenge for patients, healthcare professionals, and populations worldwide. While initial reporting focused mainly on lung involvement, the ongoing pandemic showed that multiple organs can be involved, and prognosis is largely influenced by multi-organ involvement. Our aim was to obtain nationwide retrospective population-based data on hospitalizations with COVID-19 and AKI.

29 Materials & Methods

We performed a query of G-DRG data for the year 2020 via the Institute for the hospital remuneration system (Institut für das Entgeltsystem im Krankenhaus GmbH, InEK) data portal and therefore included hospitalizations with a secondary diagnosis of RT-PCR proven COVID-19 infection, aged over 15 years. We included hospitalizations with acute kidney injury (AKI) stages 1 to 3. Age-specific and age-standardized hospitalization and in-hospital mortality rates (ASR) per 100.000 person years were calculated, with the German population of 2011 as the standard.

37 Results

In 2020, there were 16.776.845 hospitalizations in German hospitals. We detected 154.170 hospitalizations with RT-PCR proven COVID-19 diagnosis. The age-standardized hospitalization rate for COVID-19 in Germany was 232,8 per 100.000 person years (95% CI 231,6-233,9). The highest proportion of hospitalizations associated with COVID-19 were in the age group over 80 years. AKI was diagnosed in 16.773 (10,9%) of the hospitalizations

3

43 with COVID-19. The relative risk of AKI for males was 1,49 (95%CI 1,44-1,53) compared to 44 females. Renal replacement therapy (RRT) was performed in 3.443 hospitalizations, 20,5% 45 of the hospitalizations with AKI. For all hospitalizations with COVID-19, the in-hospital 46 mortality amounted to 19,7% (n= 30.300). The relative risk for in-hospital mortality was 3,87 47 (95%CI 3,80-3,94) when AKI occurred. The age-standardized hospitalization rates for COVID-48 19 took a bimodal course during the observation period. The first peak occurred in April 49 (ASR 23,95 per 100.000 person years (95%CI 23,58-24,33)), hospitalizations peaked again in 50 November 2020 (72,82 per 100.000 person years (95%Cl 72,17-73,48)). The standardized 51 rate ratios (SRR) for AKI and AKI-related mortality with the overall ASR for COVID-19 52 hospitalizations in the denominator, decreased throughout the observation period and 53 remained lower in autumn than they were in spring. In contrast to all COVID-19 54 hospitalizations, the SRR for overall mortality in COVID-19 hospitalizations diverged from 55 hospitalizations with AKI in autumn 2020.

56 Discussion

57 Our study for the first time provides nationwide data on COVID-19 related hospitalizations 58 and acute kidney injury in Germany in 2020. AKI was a relevant complication and associated 59 with high mortality. We observed a less pronounced increase in the ASR for AKI-related 60 mortality during autumn 2020. The proportion of AKI-related mortality in comparison to the 61 overall mortality decreased throughout the course of the pandemic.

62

64 Introduction

65 The SARS-CoV-2 pandemic is a major challenge for patients, healthcare professionals, and 66 populations worldwide. While initial reporting focused mainly on lung involvement, the 67 ongoing pandemic showed that multiple organs can be involved, and prognosis is largely 68 influenced by multi-organ involvement. According to published data, the kidney is the 69 second most involved organ. In a study from the New York City area, 22,2% of hospitalized 70 patients showed acute kidney injury (AKI)(1). A meta-analysis (2) confirmed the high AKI 71 rate among COVID-19 patients. In contrast to this, there is also data with lower incidence of 72 AKI(3,4) especially early analysis from Wuhan, China did not show high incidence rates of 73 AKI (3–5). However, different definitions of AKI complicate comparability. In critically ill 74 patients with COVID-19 as many as 55 to 90% experienced AKI (6-8), of whom 21 to 37% 75 required renal replacement therapy (RRT) (6,8,9). The mortality rates of patients with acute 76 kidney injury are significantly higher than in patients without AKI. In a study by Chan et al. 77 (9), the in-hospital mortality was 50% among patients with, versus 8% among those without 78 AKI. An analysis by Fisher et al. (8) found similar mortality rates (52% vs. 19.6%). In addition, 79 the length of stay (LOS) was markedly prolonged when AKI occurred (9,10).

The German healthcare system offers comprehensive insurance coverage and, by international comparison, a high level of healthcare services. Throughout the COVID-19 pandemic there were no apparent acute care resource limitations, and the hospital capacities were at their limit but not overwhelmed. Nationwide unselected data, especially covering a longer time interval is not available. There is one observational study, which included 10.021 hospitalizations (11). The data from this study was obtained from one

5

86 German health insurance company and covered a short period of time (from February 26

87 until April 19, 2020). In this study, AKI was not addressed.

Our aim was to obtain nationwide retrospective population-based data on hospitalizations with COVID-19 and AKI. Our query covered data from the year 2020 and contains, to our knowledge, the most comprehensive data regarding patients with COVID-19 and AKI in Germany.

92 Materials & Methods

93 Data Source

94 In accordance with the German Hospital Financing Act (KHG), a universal, performance-95 based remuneration system was introduced for general hospital services. The basis for this 96 is the German-Diagnosis Related Groups system (G-DRG system), whereby each inpatient 97 case of treatment is remunerated by means of a corresponding DRG rate. All hospitals 98 submit their hospitalization data to the Institute for the hospital remuneration system 99 (Institut für das Entgeltsystem im Krankenhaus GmbH, InEK). After submission, a plausibility 100 control of the data is carried out by InEK. The submission of hospitalization data is 101 mandatory for reimbursement of hospital stays. This leads to a strong incentive for hospitals 102 to supply complete data, covering virtually every hospital in Germany. The transferred data 103 include information on age, sex, discharge type, primary and secondary ICD-10-GM(12) 104 coded diagnosis (International Classification of Diseases, 10th Edition, German Modification 105 Version 2020) and performed operations and procedures (Operationen- und 106 Prozedurenschlüssel Version 2020, OPS) (13). We performed a query of G-DRG data for the 107 year 2020 via the InEK data portal (https://datenbrowser.inek.org/). The InEK data are

6

available in aggregated form, so that differentiation by federal state is not possible.
Differentiation by age can only be made in the predefined age groups and differentiation by
gender only indirectly. The G-DRG data provided by InEK have been described in detail
elsewhere (14).

112 Cohort selection

113 We included hospitalizations with a secondary diagnosis of RT-PCR proven COVID-19 114 infection (ICD-10-GM: U07.1), aged over 15 years. We excluded hospitalizations 15.525 115 (9,1%) with hospital transfer and unknown discharge status from our analysis. We identified 116 hospitalizations with acute kidney injury by their corresponding ICD-10-GM codes (S1 117 Table). We included hospitalizations with acute kidney injury stages 1 to 3 (AKIN 1 to 3) (15). 118 We further searched for OPS codes indicating hemodialysis and mechanical ventilation (S1 119 Table). The survival status at the end of each hospitalization was obtained by discharge 120 type. The observation period was from 01.02.2020 throughout 31.12.2020.

121 Statistical analysis

122 We calculated crude, age-specific and age-standardized hospitalization rates (ASR) per 123 100.000 person years and the respective 95% confidence intervals (95% CI). We used the 124 standard population of Germany in 2011 (16), provided by the Federal Bureau of Statistics 125 (DESTATIS), for direct age-standardization (S2 Table). We further calculated standardized 126 rate ratios (SRR), with their respective confidence intervals. Continuous variables are 127 reported with standard deviation (SD). Categorical data is reported in absolute numbers and 128 percentages. We used the ICD-10 version of the Elixhauser comorbidity index (ECI) to assess 129 comorbidities (17). We excluded acute kidney injury as a comorbidity. All data analysis was

- 130 carried out using R (Version 3.6.3) (18), for direct age-standardization the epitools package
- 131 (19) was used, contingency tables were evaluated using the epiR package (20).

8

132 Results

133 General characteristics and age-standardized rates

- 134 In 2020, there were 16.776.845 hospitalizations in German hospitals. We detected 154.170
- 135 hospitalizations with RT-PCR proven COVID-19 diagnosis throughout the observation period.
- 136 There were 79.781 (51,8%) male and 74.382 (48,2%) female patients hospitalized,
- respectively (Table 1). In 29.329 (19,0%) of the COVID-19 associated hospitalizations the
- 138 treatment included an intensive care unit (ICU) stay. The age-standardized hospitalization
- 139 rate for COVID-19 in Germany was 232,8 per 100.000 person years (95% CI 231,6-233,9) in
- 140 2020. Most hospitalizations (1394,1 per 100.000 person years) occurred in the age group of
- 141 80 years and older (Fig 1).

142

143

144

145

146

147

- 148
- 149

9

	AKI		ICU		Overall		
N	16.773		29.329		154.170		
Gender	%	n	%	n	%	n	
male	61,5 (1	.0.308)	62,6 (1	18.361)	51,8 (7	51,8 (79.781)	
female	38,5 (6.463)	37,4 (1	37,4 (10.965)		48,2 (74.382)	
Age group (years)	%	n	%	n	%	n	
16-17	0,0%	1	0,1%	38	0,3%	472	
18-29	0,4%	70	1,7%	493	4,0%	6143	
30-39	0,7%	112	2,8%	829	5,3%	8185	
40-49	1,9%	326	5,8%	1704	7,5%	11601	
50-54	2,6%	443	5,8%	1688	6,2%	9537	
55-59	4,5%	754	7,9%	2312	7,5%	11602	
60-64	6,8%	1134	9,6%	2818	7,7%	11858	
65-74	20,3%	3408	21,8%	6398	16,5%	25418	
75-79	17,0%	2851	14,6%	4282	11,7%	18045	
80+	45,8%	7674	29,9%	8767	33,3%	51309	
length of stay (days, SD)	18,4	(16,9)	18,3	(16,7)	11,3	(11,9)	
Elixhauser comorbidity index (%, n)	%	n	%	n	%	n	
0	60 (10	0.041)	65 (18	8.918)	65 (99	9.783)	
1-4	24 (4.029)		25 (7.186)		25 (39.117)		
>=5	16 (2.703)		10 (3.225)		10 (1	10 (15.270)	
mean (SD)	2,0	(3,8)	1,6	(3,8)	1,2	(3,1)	

151 Table 1. General characteristics of COVID-19 hospitalizations in Germany 2020.

152 ICU: intensive care unit - hospitalizations with intensive care treatment during the hospital

153 stay, AKI: acute kidney injury - hospitalizations with acute kidney injury (Acute kidney injury

154 network Stage 1-3), SD: standard deviation

- 156 Fig 1. Age-specific rates of COVID-19 hospitalizations in Germany 2020 (per 100.000 person
- 157 years)

158 Hospital incidence of acute kidney injury

159 Acute kidney injury, including AKI Stages 1-3, was diagnosed in 16.773 (10,9%) of the 160 hospitalized cases with COVID-19. The ASR for AKI was 25.8 (95%CI 25.4-26.2) per 100.000 161 person years (Table 2). While men and women were equally distributed among those 162 hospitalized for COVID-19, men were more affected by AKI than women. The relative risk of 163 AKI for males was 1,49 (95%CI 1,44-1,53) compared to females hospitalized with COVID-19 164 (S2 Table). We determined 10.310 (61,5%) male and 6.463 (38,5%) female hospitalizations 165 with acute kidney injury, respectively (Table 1). The proportion of the severity of acute 166 kidney injury was distributed as follows: 32,0% (n= 5.407) developed AKI Stage 1, AKI Stage 167 2 was present in 27,4 % (n= 4.625) and in 40,6% (n= 6.842) AKI Stage 3 was coded. There 168 were 101 hospitalizations with more than one code for AKI. When acute kidney injury was 169 present during hospital stay, 8.374 (49,9%) needed intensive care. Furthermore, mechanical 170 ventilation was required in 7.050 (42,0 %) hospitalizations with acute kidney injury (Table 2). 171 The relative risk for hospitalizations with AKI to be treated in an intensive care unit was 3,27 172 (95%CI 3,21-3,34) (Table 3).

	AKI		ICU		Overall	
	n	%	n	%	n	%
Overall	16.773	(10,9%)	29.329 (19,0%)		154.170 (-)	
Renal replacement	3.443 (20,5	5%)	3.046 (10,4	1%)	-	
therapy						
males	2.635	76,5%	2.335	76,7%	-	-
females	808	23,5%	711	23,3%	-	-
In-hospital mortality	9.717 (57,9%)	12.322 (40,6%)	30.300 (19,7%)	
males	6.283	64,7%	7.990	64,8%	17.635	58,2%
females	3.434	35,3%	4.330	35,2%	12.665	41,8%
AKI Stages						
1	5.407	32,0%	1.865	20,3%	-	
2	4.625	27,4%	2.011	21,8%	-	
3	6.842	40,6%	5.333	57,9%	-	
Chronic kidney 5.524 (32,9%)		5.365 (18,3%)		23.380 (15,2%)		
disease				_		
G3	3.638	21,7%	3.225	11,0%	15.270	9,9%
G4	1.490	8,9%	1.084	3,7%	4.535	2,9%
G5	396	2,4%	1.056	3,6%	3.575	2,3%
Mechanical	7.050 (4	42,0%)	17.144 (58,5%)		-
ventilation		1				
males	5.052	71,6%	11.508	67,1%	-	
females	1.998	28,3%	5.634	32,9%	-	
Age-standardized rate	25,8 (25,4-26,2)		44,0 (43,5-44,5)		232,8 (231,6-233,9)	
(per 100.000 PYRs, 95% Cl)						

173

174 Table 2: Results COVID-19 hospitalizations in Germany 2020,

175 ICU: intensive care unit - hospitalizations with intensive care treatment during the hospital

176 stay, AKI: acute kidney injury - hospitalizations with acute kidney injury (acute kidney injury

177 network, Stage 1-3), 95%CI: 95 % confidence interval, PYRs: person years

178

13

180

	ICU		Non-ICU		Overall
	N	%	N	%	n
AKI	8.374	49,9	8.399	50,1	16.773
Non-AKI	20.955	15,3%	116.442	84,7%	137.397
Overall	29.329	19,0%	124.841	81,0%	154.170
	Dece	Deceased		Alive	
	N	%	N	%	N
AKI	9.717	57,9%	7.056	42,1%	16.773
Non-AKI	20.583	15,0%	116.814	85,0%	137.397
Overall	30.300	19,7%	123.870	80,3%	154.170

181

182 Table 3: Contingency table for AKI and risk of ICU admission or in-hospital mortality,

183 ICU: intensive care unit - hospitalizations with intensive care treatment during the hospital

184 stay, AKI: acute kidney injury - hospitalizations with acute kidney injury (acute kidney injury

185 network, Stage 1-3)

14

186 Renal replacement therapy

187	When acute kidney injury was present, renal replacement therapy (RRT) was performed in
188	3.443 hospitalizations, 20,5% of hospitalizations with AKI and 2,2% of all COVID-19
189	associated hospitalizations. Furthermore, when RRT was conducted, mechanical ventilation
190	was needed in 2.380 (69,1%) cases. The modality of renal replacement therapy was
191	intermittent RRT in 230 (6,7%), and continuous or prolongend intermittend RRT in 3.213
192	(93,3%) hospitalizations, respectively. In 828 (24,0%) hospitalizations more than one
193	procedure code indicating RRT was present.
194	Chronic kidney disease (CKD Stages 3 to 5) was present in 23.380 (15.2%) hospitalizations
195	with AKI. We observed 3.638 (21,7%) hospitalizations with AKI and CKD Stage G3, in 1.490
196	(8.9%) hospitalizations CKD G4 was prevalent and 396 (2,4%) had CKD G5, respectively.
197 198	In-hospital mortality
199	For all hospitalizations with COVID-19, the in-hospital mortality amounted to 19,7% (n=
200	30.300). Of these, 58,2% (n= 17.635) were men and 41,8% (n=12.665) were women (Table
201	2), respectively. The relative risk for in-hospital mortality for men amounted to 1,30 (95%CI
202	1,27-1,33) compared to women (S3 Table). The ASR for in-hospital mortality was 47,7
203	(95%CI 47,2-48,3) per 100.000 person years. Most deaths (511,2 per 100.000 person years)
204	were observed in the age group over 80 years of age (Fig S1). When AKI was present, 9.717
205	died, accounting for 57,9% of deaths in this group (Table 2), the relative risk for in-hospital
206	mortality was 3,87 (95%CI 3,80-3,94) when AKI occurred (Table 3). Moreover, when
207	hemodialysis was performed, 2.891 died, which amounts to 61,4% of all hospitalizations
208	with RRT.

15

209

210 Length of stay

- The mean length of stay (LOS) for hospitalizations with COVID-19 was 11,3 days (SD 11,9).
- 212 When acute kidney injury was coded, the LOS increased to 18,4 days (SD 16,9). For cases
- that had an ICU stay the mean LOS was 18,3 days (SD 16,7) (Table 1).

214 Time course of hospitalization rates and in-hospital mortality

215

The age-standardized hospitalization rates for COVID-19 took a bimodal course during the observation period. The first peak of ASR occurred in April 2020 (23,95 per 100.000 person years (95%Cl 23,58-24,33)), after the ASR rose steadily beginning in February. Subsequently, ASR for COVID-19 hospitalizations peaked again in November 2020 (72,82 per 100.000 person years (95%Cl 72,17-73,48)). In comparison to the first peak, ASR rose steadily for two months before reaching the highest rates (Fig 2A).

The ASR for AKI and AKI-related mortality took a flatter curve, but overall follow a similar bimodal course. The ASR for AKI and AKI-related mortality reached their peak in March 2020 (for AKI 3,4 per 100.000 person years (95%CI 3,27-3,55), which was also when AKI-related mortality reached 2,07 (95%CI 1,96-2,18), respectively). In November 2020 ASR tipped again when ASR for AKI stood at 8,07 per 100.000 person years (95%CI 7,85-8,29), and the ASR for AKI-related mortality rose to 4,65 (95%CI 4,49-4,82)) (Fig 2A).

The standardized rate ratios (SRR) for AKI and AKI-related mortality with the overall ASR for COVID-19 hospitalizations in the denominator, actually decreased throughout the observation period (Fig 2B) and remained lower in autumn than they were in spring. In

medRxiv preprint doi: https://doi.org/10.1101/2021.04.30.21256331; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

16

23	l contrast to this	finding, the ASR and	in particular the SRR f	for overall mort	ality in COVID-19
----	--------------------	----------------------	-------------------------	------------------	-------------------

hospitalizations rose sharply again as early as September 2020 (Fig 3A and 3B).

The distribution of age groups varied throughout the observation period. In particular, the age group of 80 years and above were most prevalent in the months of April, November and December (Fig S4). Hospitalizations in which AKI was coded, were proportionately much older, with the 80 years and above age group being the most represented (Fig S5).

Fig 2: A) Time course of age-standardized rates (per 100.00 person years) of overall hospitalization, AKI and AKI-related mortality for COVID-19 in Germany (2020); B) Standardized rate ratios (SRR) of AKI age-standardized rates (per 100.00 person years) and AKI-related mortality in relation to the overall age-standardized COVID-19 hospitalization rate in Germany (2020)

Fig 3: A) Time course of age-standardized rates (per 100.00 person years) of overall hospitalization and overall mortality for COVID-19 in Germany (2020); B) Standardized rate ratios (SRR) of overall mortality age-standardized rates (per 100.00 person years) in relation to the overall age-standardized COVID-19 hospitalization rate in Germany (2020)

246 Comorbidities

The Elixhauser comorbidity index (ECI) varied among the different groups. The mean ECI for all COVID-19 associated hospitalizations was 1,2 (SD 3,1). For hospitalizations requiring intensive care the mean ECI was 1,6 (SD 3,8). When acute kidney injury was present the ECI increased to 2,0 (SD 3,8). In general, the four most common coded comorbidities were uncomplicated hypertension (35,3%), fluid and electrolyte disorders (20,6%), uncomplicated diabetes mellitus (13,3%) and cardiac arrhythmias (10,0%) (Fig 4). When acute kidney injury

17

253 or an ICU stay were coded, cardiac arrhythmias were relatively more prevalent compared to

all hospitalizations with COVID-19 (Fig S2, S3).

255 Fig 4: Relative frequencies of comorbidities in COVID-19 hospitalizations in Germany 2020.

256 chf: congestive heart failure; carit: cardiac arrhythmias; valv: valvular disease; pcd: pulmonary circulation 257 disorders; pvd: peripheral vascular disorders; hypunc: hypertension - uncomplicated; hypc: hypertension 258 complicated; para: paralysis; ond: other neurological disorders; cpd: chronic pulmonary disease; 259 diabunc: diabetes -uncomplicated; diabc: diabetes- complicated; hypothy: hypothyroidism; ld: liver 260 disease; pud: peptic ulcer disease- excluding bleeding; aids: AIDS/HIV; lymph: lymphoma; metacanc: 261 metastatic cancer; solidtum: solid tumour: without metastasis; rheumd: rheumatoid arthritis/collaged 262 vascular disease; coag: coagulopathy; obes: obesity; wloss: weight loss; fed: fluid and electrolyte 263 disorders; blane: blood loss anaemia; dane: deficiency anaemia; alcohol: alcohol abuse; drug: drug abuse; 264 psycho: psychoses; depre: depression;

266 **Discussion**

265

267 Our study for the first time provides nationwide data on COVID-19 hospitalizations and 268 acute kidney injury in Germany in 2020. The key findings that emerge from our data are as 269 follows. The highest proportion of hospitalizations associated with COVID-19 were in the 270 age group over 80 years. The gender distribution was equal in COVID-19 related 271 hospitalization, however, we observed that men more often developed acute kidney injury 272 (RR 1,49 (95%CI 1,44-1,53)), needed ICU care and had a higher risk of in-hospital mortality 273 (RR: 1,30 (95%CI 1,27-1,33)) than women. Our results thus exhibit a gender bias. This is 274 consistent with a meta-analysis including 3.111.714 COVID-19 associated hospitalizations 275 worldwide, which identified male sex as a risk factor for death and ICU-admission, despite 276 the gender ratio being equal at the time of admission (21). Different underlying 277 mechanisms - from hormonal, genetic to behavioral effects and risk factor prevalence -278 have been discussed in the literature (21,22).

medRxiv preprint doi: https://doi.org/10.1101/2021.04.30.21256331; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

18

Overall, 19 % of all hospitalizations needed intensive care treatment. This fraction was particularly high in patients with acute kidney injury. This finding is in line with other studies (23,24). There are no clearly defined criteria for ICU admission in COVID-19 hospitalized patients. Germany possesses the highest capacity of intensive care beds in all OECDcountries. Despite the presumably higher availability of ICU capacity, this fact did not lead to higher utilization of these capacities. This could be an indicator that the percentage of critically ill patients was similar compared to different countries (23).

286 Occurrence of AKI considerably differs in previous studies, partly due to a different 287 definition of AKI. Our analysis showed that 10.9% of all hospitalizations experienced acute 288 kidney injury. The incidence of AKI in this national series is lower than what has been 289 reported in regionally confined studies from the United States (8,9,23). A meta-analysis by 290 Gabarre et al. (2) rendered similar results to our figures. They observed an average AKI 291 incidence of 11% (95%CI 8–17%) overall, with highest ranges in the critically ill (23% (95%CI 292 14–35%)). Nevertheless, the age structure, risk factor prevalence and the burden of COVID-293 19 during the observation period differ relevantly between countries and the AKI rate is 294 therefore only comparable to a limited extend.

A large proportion of patients with acute kidney injury suffered severe kidney injury (AKIN Stage 3: 40,6%), this is consistent with previous findings (9). In the group of hospitalization with AKI 49,9% required ICU admission compared to 15,2 % of patients without AKI. The relative risk to be treated in an ICU was 3,27 for AKI patients. Moreover, in the group with AKI, 42,0 % required mechanical ventilation. Data from the early phase of the pandemic in New York state estimated that 53,6% of AKI patients needed invasive ventilation (10). This higher numbers are likely reflective of more severe disease outcomes in patients with AKI.

19

302 RRT was required in 2,2% of all hospitalizations. Among patients with AKI 20,5% required 303 RRT. This figure is consistent with data from various studies (6,9,25). The majority (88,5%) of 304 the RRT was performed in the intensive care unit. 69,1 % of all patients requiring dialysis 305 needed invasive ventilation. Similar findings were reported in a multi-center cohort study 306 from the United States (6). Previous studies suggested that there is an association between 307 mechanical ventilation, AKI and RRT. RRT often occurs around time of intubation, suggesting 308 a role for altered hemodynamics in this situation (6,10). Hence, vasopressors are often 309 initiated around this time.

310 The overall in-hospital mortality for COVID-19 associated hospitalizations vary across 311 different countries and cohorts, showing differences in testing and case identification, 312 variable thresholds for hospitalization and staff capacities. Therefore, differences in in-313 hospital mortality ranged between 15 to 20% (26,27). Our analysis showed that 30.300 314 (19.7%) of hospitalizations with COVID-19 ultimately deceased, of 154.170 initially admitted 315 to hospital. In-hospital mortality was 57.9% among patients with AKI versus 15% among 316 those without AKI. This finding underlines the poor prognosis of these patients and the 317 severity of disease.

The age-standardized hospitalization rate due to COVID-19 in 2020 was bimodally shaped, with peak rates in April and November. This observation is congruent with the incidence figures reported by the Robert Koch Institute (28). The first peak with increasing mortality rates in March and April was followed by a decline in mortality rates and a concomitant decrease in hospital admissions. Similar results have already been demonstrated in various studies from other countries. In a data-analysis from the United States a decrease in the risk-adjusted mortality was observed, ranging from 16.56 % to 9.29% in the early period of

20

325 this study (January through April 2020) compared with the later period (May through June 326 2020) (29). Further, national ICU data from the United Kingdom – published as a preprint up 327 to now - confirmed this finding. The authors found a reduction in mortality rates from 41,4% 328 in March 2020 to 24,8% in June 2020 (30). The underlying reason for the decrease of 329 mortality rates is not obvious and certainly multifactorial. One important factor was 330 certainly the concomitant decline in the incidence rate in the UK and the US. For example, a 331 large US study of health insurance data, involving more than 38.517 patients, revealed that 332 the strongest determinant of improvements in in-hospital outcome was a decline in 333 community rates of infection (29). Other reasons might be a shift in demographics, 334 experience in physicians to early diagnose and treat COVID-19 patients, hospitals and staff 335 became less overwhelmed during time. In our data during the second peak in COVID-19 336 hospitalizations, which was more pronounced than the first, the in-hospital mortality rate 337 increased steadily from September to December and exceeded the COVID-19 associated in-338 hospital mortality in March and April markedly (5,36 per 100.000 person years in April and 339 16,15 per 100.000 person years in December). One can only speculate about the factors that 340 led to this development. One, but certainly not the only, explanation could be a different 341 age distribution of patients admitted to the hospital with a higher proportion of older 342 patients in November and December, as in our data (Fig S4, Fig S5). Further, multiple factors 343 might have influenced in-hospital mortality. The increasing number of patients in need of 344 critical care could have overwhelmed hospitals regionally, which happened for example in 345 Saxony, Germany in December 2020. As already mentioned, an American study has shown 346 that hospitals did better when the prevalence of COVID-19 in their surrounding 347 communities was lower(29). Another contributing factor could have been staff shortages 348 driven by COVID-19 infections, school lockdowns, quarantine regulations and the necessity

21

349 to take care of relatives infected with COVID-19 or in quarantine. In contrast to the 350 development discussed above, the ASR for AKI and AKI-related mortality had a 351 disproportionately smaller increase and were already declining in December. The age 352 distribution in our cohort was similar among all hospitalized patients, with a higher 353 proportion of elderly patients in the second peak in October, November and December in 354 comparison to February, March and April. Thus, differences in age distribution is not a good 355 explanation for this finding (S4 Fig and S5). At this point, it must be said again that multiple 356 factors could have influenced the ASR for AKI und AKI-related mortality. Apart from 357 differences in the patient population or age distribution, changes in the treatment strategy -358 e.g., the early use of drug therapies for patients with an increased risk of severe COVID-19 359 courses.

360 The mean length of stay (LOS- discharged or dead) of all patients was 11,3 days and 361 increased with AKI to 18,4 days. LOS varies in different studies, and - according to a 362 systematic review by Rees et al. (31) - the median LOS was 14 days in China, compared with 363 5 (IQR 3–9) days outside of China. Similar figures were reported by Fisher et al. (8). This may 364 be explained by many differences in criteria for admission and discharge between countries, 365 and different timings in the course of the pandemic. Hospital capacities in Germany were 366 not overwhelmed by the pandemic, and the pressure to discharge patients might have been 367 lower. The most comprehensive analysis of German patients to date included 10.021 368 patients with a mean LOS of 14,3 days (32). This was longer than in our analysis, an 369 explanation for the discrepancy could be timing of data collection. Karagiannidis et al. 370 collected their data at the beginning of the pandemic. Due to an increasing experience in

22

371 treating COVID-19 patients and new treatment options, the length of stay consequently372 declined.

The observed comorbidities varied between the different groups. Hypertension, diabetes mellitus, fluid and electrolyte disorders and cardiac arrhythmias were the most commonly coded comorbidities. This finding is plausible, as these are the most common comorbidities in patients with chronic kidney disease (33) and likewise known risk factors for hospitalization with COVID-19 (34). Cardiac arrhythmias became more prevalent in hospitalizations with AKI. Cardiac arrhythmias are a common finding in COVID-19, in particular with an increasing number of comorbidities (35).

380 Strengths and limitations

381 The major strength of this study is that we provide a nationwide population-based view on 382 COVID-19 hospitalizations with acute kidney injury in Germany. We retrieved DRG-data 383 covering virtually every hospital in Germany. In this study, we use routine hospitalization 384 data, which is lacking clinical detail. This might lead to confounding that we could not adjust 385 for. The InEK provides aggregated data due to data safety precautions, which is fully 386 anonymized. It is, therefore, possible that this could lead to bias caused by readmission, 387 though this possibility is limited, because of the severity of most cases and our efforts to 388 exclude readmissions from the dataset. Another important fact to consider, when analyzing 389 routine data, is the observation period. In our analysis the observation period ends in the 390 midst of the second wave of the COVID-19 pandemic in Germany. This will lead to bias, as 391 the outcome of these cases remains unknown, in particular for hospitalizations in the last 392 month of the observation period.

395 Bibliography

- Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al.
 Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients
 Hospitalized with COVID-19 in the New York City Area. JAMA Journal of the
 American Medical Association. 2020;323(20):2052–9.
- 400 2. Gabarre P, Dumas G, Dupont T, Darmon M, Azoulay E, Zafrani L. Acute kidney injury 401 in critically ill patients with COVID-19. Intensive Care Medicine [Internet].
- 402 2020;46(7):1339–48. Available from: https://doi.org/10.1007/s00134-020-06153-9
- Wang L, Li X, Chen H, Yan S, Li D, Li Y, et al. Coronavirus disease 19 infection does not
 result in acute kidney injury: An analysis of 116 hospitalized patients from Wuhan,
 China. American Journal of Nephrology. 2020;51(5):343–8.
- 406 4. Yang X, Jin Y, Li R, Zhang Z, Sun R, Chen D. Prevalence and impact of acute renal
 407 impairment on COVID-19: A systematic review and meta-analysis. Critical Care.
 408 2020;24(1):1-8.
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for
 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort
 study. The Lancet [Internet]. 2020;395(10229):1054–62. Available from:
 http://dx.doi.org/10.1016/S0140-6736(20)30566-3
- Gupta S, Coca SG, Chan L, Melamed ML, Brenner SK, Hayek SS, et al. AKI treated with
 renal replacement therapy in critically ill patients with COVID-19. Journal of the
 American Society of Nephrology. 2021;32(1):161–76.
- Thakkar J, Chand S, Aboodi MS, Gone AR, Alahiri E, Schecter DE, et al. Characteristics,
 Outcomes and 60-Day Hospital Mortality of ICU Patients with COVID-19 and Acute
 Kidney Injury. Kidney360. 2020;1(12):1339–44.

419	8.	Fisher M, Neugarten J, Bellin E, Yunes M, Stahl L, Johns TS, et al. AKI in Hospitalized
420		Patients with and without COVID-19: A Comparison Study. Journal of the American
421		Society of Nephrology [Internet]. 2020 Sep 1;31(9):2145 LP – 2157. Available from:
422		http://jasn.asnjournals.org/content/31/9/2145.abstract
423	9.	Chan L, Chaudhary K, Saha A, Chauhan K, Vaid A, Zhao S, et al. AKI in hospitalized
424		patients with COVID-19. Journal of the American Society of Nephrology.

- 425 2021;32(1):151-60.
- 426 10. Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute kidney injury 427 in patients hospitalized with COVID-19. Kidney International. 2020;98(1):209–18.
- 428 11. Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al.
- 429 Case characteristics, resource use, and outcomes of 10â€^021 patients with COVID-19
 430 admitted to 920 German hospitals: an observational study. The Lancet Respiratory
 431 Medicine [Internet]. 2020 [cited 2021 Mar 11];8(9):853–62. Available from:
 432 www.thelancet.com/respiratoryVol
- 433 12. Graubner B, Auhuber TC. ICD-10-GM Version 2020, Systematisches Verzeichnis, 434 Internationale statistische Klassifikation der Krankheiten und verwandter 435 Gesundheitsprobleme, 10. Revision, Stand: 20. September 2019 [Internet]. Köln: 436 Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) im Auftrag des 437 Bundesministeriums für Gesundheit (BMG) unter Beteiligung der Arbeitsgruppe ICD 438 des Kuratoriums für Fragen der Klassifikation im Gesundheitswesen (KKG); 2019. p. 439 September 2019. Available from: www.dimdi.de - Klassifikationen - Downloads -440 ICD-10-GM - Version 2021
- 441 13. Operationen- und Prozedurenschlüssel Internationale Klassifikation der Prozeduren
 442 in der Medizin (OPS) Band 1: Systematisches Verzeichnis [Internet]. Bundesinstitut für

26

443		Arzneimittel und Medizinprodukte (BfArM) im Auftrag des Bundesministeriums für
444		Gesundheit (BMG) unter Beteiligung der Arbeitsgruppe ICD des Kuratoriums für
445		Fragen der Klassifikation im Gesundheitswesen (KKG); 2020. 740. Available from:
446		https://www.dimdi.de/dynamic/de/klassifikationen/icd/icd-10-gm/
447	14.	Busse R, Nimptsch U. COVID-19-Pandemie: Historisch niedrige Bettenauslastung.
448		Deutsches Aerzteblatt Online. 2021;118(10):10-3.
449	15.	Levin A, Warnock DG, Mehta RL, Kellum JA, Shah S v., Molitoris BA, et al. Improving
450		Outcomes From Acute Kidney Injury: Report of an Initiative. American Journal of
451		Kidney Diseases. 2007;50(1):1–4.
452	16.	Gesundheitsberichterstattung des Bundes [Internet]. 2021. Available from:
453		https://www.gbe-bund.de/gbe/pkg_isgbe5.prc_isgbe
454	17.	Quan H, Sundararajan V, Halfon P, Fong A. Coding algorithms for defining
455		comorbidities in. Medical Care [Internet]. 2005;43(11). Available from:
456		http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Coding+Algorithms
457		+for+Defining+Comorbidities+in#1%5Cnhttp://scholar.google.com/scholar?hl=en&bt
458		nG=Search&q=intitle:Coding+algorithms+for+defining+comorbidities+in#1
459	18.	Team RC. R: A Language and Environment for Statistical Computing [Internet].
460		Vienna, Austria: R Foundation for Statistical Computing; 2020. Available from: www.r-
461		project.org
462	19.	Tomas J. Aragon. epitools: Epidemiology Tools. R package version 0.5-10.1. 2020.
463	20.	Stevenson M, Sergeant E. epiR - Tools for the Analysis of Epidemiological Data. 2021.
464	21.	Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et

465 al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and

27

466 ITU admission. Nature Communications [Internet]. 2020;11(1):1–10. Available from:

- 467 http://dx.doi.org/10.1038/s41467-020-19741-6
- 468 22. Kelada M, Anto A, Dave K, Saleh SN. The Role of Sex in the Risk of Mortality From
 469 COVID-19 Amongst Adult Patients: A Systematic Review. Cureus. 2020;12(8).
- 470 23. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al.
- 471 Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients
 472 Hospitalized With COVID-19 in the New York City Area. JAMA [Internet].
 473 2020;323:2052–9. Available from: https://jamanetwork.com/
- 474 24. Fisher M, Neugarten J, Bellin E, Yunes M, Stahl L, Johns TS, et al. AKI in Hospitalized
- 475 Patients with and without COVID-19: A Comparison Study. Journal of the American
- 476 Society of Nephrology [Internet]. 2020 Sep 1;31(9):2145 LP 2157. Available from:

477 http://jasn.asnjournals.org/content/31/9/2145.abstract

- 478 25. Richards-Belle A, Orzechowska I, Doidge J, Thomas K, Harrison DA, Koelewyn A, et al.
- 479 Critical care outcomes, for the first 200 patients with confirmed COVID-19, in 480 England, Wales and Northern Ireland: A report from the ICNARC Case Mix 481 Programme. Journal of the Intensive Care Society. 2020;0(0):1–10.
- Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology,
 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A
 Review. JAMA Journal of the American Medical Association. 2020;324(8):782–93.
- 485 27. Sorci G, Faivre B, Morand S. Explaining among-country variation in COVID-19 case
 486 fatality rate. Scientific Reports. 2020 Dec 1;10(1).
- Robert Koch Institut. Total overview of cases, deaths, and 7-day incidences reported
 per day to the RKI by state and county. [Internet]. 2021. Available from:
 https://www.rki.de/DE/Content/InfAZ/N/Neuartiges Coronavirus/Daten/Fallzahlen

490	Daten.html;jsessionid=4D411DFBB2E2575A9CD1F5504E7CE3BC.internet052?nn=134
491	90888

- 492 29. Asch DA, Sheils NE, Islam MN, Chen Y, Werner RM, Buresh J, et al. Variation in US
 493 Hospital Mortality Rates for Patients Admitted with COVID-19 during the First 6
 494 Months of the Pandemic. JAMA Internal Medicine. 2020;19104(4):471–8.
- 30. Dennis JM, McGovern AP, Vollmer SJ, Mateen BA. Improving COVID-19 critical care
 mortality over time in England: A national cohort study, March to June 2020.
 medRxiv. 2020;44(0).
- 498 31. Rees EM, Nightingale ES, Jafari Y, Waterlow NR, Clifford S, Pearson CAB, et al. COVID-
- 499 19 length of hospital stay: A systematic review and data synthesis. medRxiv. 2020;
- 500 32. Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al.
- 501 Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19
- 502 admitted to 920 German hospitals: an observational study. The Lancet Respiratory
- 503 medicine [Internet]. 2020 Sep [cited 2021 Mar 11];8(9):853-62. Available from:
- 504 www.thelancet.com/respiratoryVol
- 33. Reichel H, Zee J, Tu C, Young E, Pisoni RL, Stengel B, et al. Chronic kidney disease
 progression and mortality risk profiles in Germany: Results from the Chronic Kidney
 Disease Outcomes and Practice Patterns Study. Nephrology Dialysis Transplantation.
 2020 May 1;35(5):803–10.
- 509 34. Ioannou GN, Locke E, Green P, Berry K, O'Hare AM, Shah JA, et al. Risk Factors for
 510 Hospitalization, Mechanical Ventilation, or Death Among 102131 US Veterans With
 511 SARS-CoV-2 Infection. JAMA network open. 2020;3(9):e2022310.

- 512 35. Coromilas EJ, Kochav S, Goldenthal I, Biviano A, Garan H, Goldbarg S, et al.
- 513 Worldwide Survey of COVID-19 Associated Arrhythmias. Circulation: Arrhythmia and
- 514 Electrophysiology. 2021; (March): 285–95.
- 515
- 516

30

517 Supporting information

- 518 S1 Fig. Age-specific mortality rates of COVID-19 hospitalizations in Germany 2020 (per
- 519 100.000 person years)
- 520 S2 Fig. Relative frequencies of comorbidities in COVID-19 hospitalizations with AKI in
- 521 Germany 2020.

522 chf: congestive heart failure; carit: cardiac arrhythmias; valv: valvular disease; pcd: pulmonary circulation 523 disorders; pvd: peripheral vascular disorders; hypunc: hypertension - uncomplicated; hypc: hypertension 524 - complicated; para: paralysis; ond: other neurological disorders; cpd: chronic pulmonary disease; 525 diabunc: diabetes -uncomplicated; diabc: diabetes- complicated; hypothy: hypothyroidism; ld: liver 526 disease; pud: peptic ulcer disease- excluding bleeding; aids: AIDS/HIV; lymph: lymphoma; metacanc: 527 metastatic cancer; solidtum: solid tumour: without metastasis; rheumd: rheumatoid arthritis/collaged 528 vascular disease; coag: coagulopathy; obes: obesity; wloss: weight loss; fed: fluid and electrolyte 529 disorders; blane: blood loss anaemia; dane: deficiency anaemia; alcohol: alcohol abuse; drug: drug abuse; 530 psycho: psychoses; depre: depression;

- 531
- 532
 - 32 S3 Fig. Relative frequencies of comorbidities in COVID-19 hospitalizations with ICU
- 533 treatment in Germany 2020.

534 chf: congestive heart failure; carit: cardiac arrhythmias; valv: valvular disease; pcd: pulmonary circulation 535 disorders; pvd: peripheral vascular disorders; hypunc: hypertension - uncomplicated; hype: hypertension 536 - complicated; para: paralysis; ond: other neurological disorders; cpd: chronic pulmonary disease; 537 diabunc: diabetes -uncomplicated; diabc: diabetes- complicated; hypothy: hypothyroidism; ld: liver 538 disease; pud: peptic ulcer disease- excluding bleeding; aids: AIDS/HIV; lymph: lymphoma; metacanc: 539 metastatic cancer; solidtum: solid tumour: without metastasis; rheumd: rheumatoid arthritis/collaged 540 vascular disease; coag: coagulopathy; obes: obesity; wloss: weight loss; fed: fluid and electrolyte 541 disorders; blane: blood loss anaemia; dane: deficiency anaemia; alcohol: alcohol abuse; drug: drug abuse; 542 psycho: psychoses; depre: depression;

543

544 S4 Fig. Percentage distribution of age groups during the observation period (Overall COVID-

- 545 19)
- 546 S5 Fig. Percentage distribution of age groups during the observation period (AKI)
- 547 S1 Table. List of ICD-10-GM and OPS Codes, version 2020
- 548 S2 Table. Contingency table AKI by sex

31

549 S3 Table. Contingency table in-hospital mortality by sex











